Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Sebastian Schneeweiss, Sc.D., M.D.

Co-Author

This page shows the publications co-authored by Sebastian Schneeweiss and Daniel Solomon.
Connection Strength

11.398
  1. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA. 2011 Jun 22; 305(24):2525-31.
    View in: PubMed
    Score: 0.484
  2. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med. 2010 Dec 13; 170(22):1968-76.
    View in: PubMed
    Score: 0.467
  3. The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med. 2010 Dec 13; 170(22):1979-86.
    View in: PubMed
    Score: 0.467
  4. Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis. Ann Rheum Dis. 2010 Dec; 69(12):2114-7.
    View in: PubMed
    Score: 0.452
  5. NSAID switching and short-term gastrointestinal outcome rates after the withdrawal of rofecoxib. Pharmacoepidemiol Drug Saf. 2009 Dec; 18(12):1134-42.
    View in: PubMed
    Score: 0.435
  6. The relation between bisphosphonate use and non-union of fractures of the humerus in older adults. Osteoporos Int. 2009 Jun; 20(6):895-901.
    View in: PubMed
    Score: 0.402
  7. The risk of infection associated with tumor necrosis factor alpha antagonists: making sense of epidemiologic evidence. Arthritis Rheum. 2008 Apr; 58(4):919-28.
    View in: PubMed
    Score: 0.387
  8. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum. 2007 Jun; 56(6):1754-64.
    View in: PubMed
    Score: 0.366
  9. Veteran's affairs hospital discharge databases coded serious bacterial infections accurately. J Clin Epidemiol. 2007 Apr; 60(4):397-409.
    View in: PubMed
    Score: 0.354
  10. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum. 2006 Dec; 54(12):3790-8.
    View in: PubMed
    Score: 0.353
  11. Not-so-surprising findings. CMAJ. 2006 Jul 18; 175(2):171-2; author reply 172.
    View in: PubMed
    Score: 0.344
  12. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis. 2006 Dec; 65(12):1608-12.
    View in: PubMed
    Score: 0.343
  13. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum. 2006 May; 54(5):1378-89.
    View in: PubMed
    Score: 0.339
  14. Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction. Epidemiology. 2005 Jan; 16(1):17-24.
    View in: PubMed
    Score: 0.309
  15. A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors. J Clin Epidemiol. 2005 Jan; 58(1):98-102.
    View in: PubMed
    Score: 0.309
  16. Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study. Semin Arthritis Rheum. 2019 10; 49(2):222-228.
    View in: PubMed
    Score: 0.207
  17. No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: A multi-database cohort study. Semin Arthritis Rheum. 2018 12; 48(3):399-405.
    View in: PubMed
    Score: 0.193
  18. Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study. Arthritis Rheumatol. 2017 06; 69(6):1154-1164.
    View in: PubMed
    Score: 0.182
  19. Assessment of Confounders in Comparative Effectiveness Studies From Secondary Databases. Am J Epidemiol. 2017 03 15; 185(6):474-478.
    View in: PubMed
    Score: 0.180
  20. Biologic Disease-Modifying Antirheumatic Drugs and Risk of High-Grade Cervical Dysplasia and Cervical Cancer in Rheumatoid Arthritis: A Cohort Study. Arthritis Rheumatol. 2016 09; 68(9):2106-13.
    View in: PubMed
    Score: 0.174
  21. Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study. Am J Med. 2015 Jun; 128(6):653.e7-653.e16.
    View in: PubMed
    Score: 0.156
  22. Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs. Am J Med. 2015 May; 128(5):539.e7-17.
    View in: PubMed
    Score: 0.154
  23. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study. Ann Rheum Dis. 2015 Nov; 74(11):1968-75.
    View in: PubMed
    Score: 0.149
  24. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study. Ann Rheum Dis. 2015 Jul; 74(7):1360-7.
    View in: PubMed
    Score: 0.146
  25. Clinical and health care use characteristics of patients newly starting allopurinol, febuxostat, and colchicine for the treatment of gout. Arthritis Care Res (Hoboken). 2013 Dec; 65(12):2008-14.
    View in: PubMed
    Score: 0.143
  26. Risk of venous thromboembolism in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013 Oct; 65(10):1600-7.
    View in: PubMed
    Score: 0.142
  27. Validation of claims-based algorithms for identification of high-grade cervical dysplasia and cervical cancer. Pharmacoepidemiol Drug Saf. 2013 Nov; 22(11):1239-44.
    View in: PubMed
    Score: 0.141
  28. Matching by propensity score in cohort studies with three treatment groups. Epidemiology. 2013 May; 24(3):401-9.
    View in: PubMed
    Score: 0.138
  29. Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments. BMC Med Res Methodol. 2012 Nov 26; 12:180.
    View in: PubMed
    Score: 0.134
  30. No differences in cancer screening rates in patients with rheumatoid arthritis compared to the general population. Arthritis Rheum. 2012 Oct; 64(10):3076-82.
    View in: PubMed
    Score: 0.132
  31. Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges. Osteoporos Int. 2013 Jan; 24(1):237-44.
    View in: PubMed
    Score: 0.130
  32. Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study. J Bone Miner Res. 2012 Apr; 27(4):789-96.
    View in: PubMed
    Score: 0.128
  33. Simultaneously assessing intended and unintended treatment effects of multiple treatment options: a pragmatic "matrix design". Pharmacoepidemiol Drug Saf. 2011 Jul; 20(7):675-83.
    View in: PubMed
    Score: 0.121
  34. Accuracy of identifying neutropenia diagnoses in outpatient claims data. Pharmacoepidemiol Drug Saf. 2011 Jul; 20(7):709-13.
    View in: PubMed
    Score: 0.120
  35. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. J Bone Miner Res. 2011 May; 26(5):993-1001.
    View in: PubMed
    Score: 0.120
  36. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. J Bone Miner Res. 2010 Nov 18.
    View in: PubMed
    Score: 0.116
  37. Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis. Arthritis Res Ther. 2010; 12(4):R154.
    View in: PubMed
    Score: 0.114
  38. Privacy-maintaining propensity score-based pooling of multiple databases applied to a study of biologics. Med Care. 2010 Jun; 48(6 Suppl):S83-9.
    View in: PubMed
    Score: 0.113
  39. Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years' data. Arch Gen Psychiatry. 2010 May; 67(5):497-506.
    View in: PubMed
    Score: 0.112
  40. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther. 2009 Aug; 30(3):253-64.
    View in: PubMed
    Score: 0.104
  41. Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study. Arthritis Res Ther. 2008; 10(4):R95.
    View in: PubMed
    Score: 0.099
  42. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum. 2008 Aug 15; 59(8):1097-104.
    View in: PubMed
    Score: 0.099
  43. Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J. 2008 Aug; 156(2):336-41.
    View in: PubMed
    Score: 0.098
  44. Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal. Arthritis Rheum. 2007 Aug 15; 57(6):928-34.
    View in: PubMed
    Score: 0.093
  45. Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med. 2007 Apr 23; 167(8):847-52.
    View in: PubMed
    Score: 0.091
  46. Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data. Cancer Causes Control. 2007 Jun; 18(5):561-9.
    View in: PubMed
    Score: 0.091
  47. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis. Arthritis Rheum. 2006 Nov; 54(11):3390-8.
    View in: PubMed
    Score: 0.088
  48. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum. 2006 Sep; 54(9):2757-64.
    View in: PubMed
    Score: 0.087
  49. Prior authorization policies for selective cyclooxygenase-2 inhibitors in Medicaid: a policy review. Med Care. 2006 Jul; 44(7):658-63.
    View in: PubMed
    Score: 0.086
  50. Instrumental variable analysis of secondary pharmacoepidemiologic data. Epidemiology. 2006 Jul; 17(4):373-4.
    View in: PubMed
    Score: 0.086
  51. Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology. 2006 May; 17(3):268-75.
    View in: PubMed
    Score: 0.085
  52. The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28. Arthritis Res Ther. 2006; 8(3):R57.
    View in: PubMed
    Score: 0.084
  53. Bone mineral density in subjects using central nervous system-active medications. Am J Med. 2005 Dec; 118(12):1414.
    View in: PubMed
    Score: 0.082
  54. Explained variation in a model of therapeutic decision making is partitioned across patient, physician, and clinic factors. J Clin Epidemiol. 2006 Jan; 59(1):18-25.
    View in: PubMed
    Score: 0.082
  55. Performance of a rheumatoid arthritis records-based index of severity. J Rheumatol. 2005 Sep; 32(9):1679-87.
    View in: PubMed
    Score: 0.081
  56. Identification of individuals with CKD from Medicare claims data: a validation study. Am J Kidney Dis. 2005 Aug; 46(2):225-32.
    View in: PubMed
    Score: 0.081
  57. Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med. 2004 Nov 18; 351(21):2187-94.
    View in: PubMed
    Score: 0.077
  58. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J. 2004 Jul; 148(1):99-104.
    View in: PubMed
    Score: 0.075
  59. Relationship between COX-2 specific inhibitors and hypertension. Hypertension. 2004 Aug; 44(2):140-5.
    View in: PubMed
    Score: 0.075
  60. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation. 2004 May 04; 109(17):2068-73.
    View in: PubMed
    Score: 0.074
  61. Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important? Am J Med. 2003 Dec 15; 115(9):715-20.
    View in: PubMed
    Score: 0.072
  62. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. Ann Rheum Dis. 2019 04; 78(4):456-464.
    View in: PubMed
    Score: 0.051
  63. Tumor Necrosis Factor-a Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid Arthritis. Epidemiology. 2016 May; 27(3):414-22.
    View in: PubMed
    Score: 0.042
  64. The impact of reducing cardiovascular medication copayments on health spending and resource utilization. J Am Coll Cardiol. 2012 Oct 30; 60(18):1817-24.
    View in: PubMed
    Score: 0.033
  65. At Pitney Bowes, value-based insurance design cut copayments and increased drug adherence. Health Aff (Millwood). 2010 Nov; 29(11):1995-2001.
    View in: PubMed
    Score: 0.029
  66. An evaluation of the relationship between the implementation of a newly designed prescription drug label at Target pharmacies and health outcomes. Med Care. 2009 Sep; 47(9):1031-5.
    View in: PubMed
    Score: 0.027
  67. Can improved prescription medication labeling influence adherence to chronic medications? An evaluation of the Target pharmacy label. J Gen Intern Med. 2009 May; 24(5):570-8.
    View in: PubMed
    Score: 0.026
  68. Rationale and design of the Study Assessing the Effect of Cardiovascular Medications Provided as Low-cost, Evidence-based Generic Samples (SAMPLES) trial. Am Heart J. 2009 Apr; 157(4):613-9.
    View in: PubMed
    Score: 0.026
  69. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005 Dec 01; 353(22):2335-41.
    View in: PubMed
    Score: 0.021
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.